AU5845594A - Cancerous b cell treatment using substituted nucleoside derivatives - Google Patents
Cancerous b cell treatment using substituted nucleoside derivativesInfo
- Publication number
- AU5845594A AU5845594A AU58455/94A AU5845594A AU5845594A AU 5845594 A AU5845594 A AU 5845594A AU 58455/94 A AU58455/94 A AU 58455/94A AU 5845594 A AU5845594 A AU 5845594A AU 5845594 A AU5845594 A AU 5845594A
- Authority
- AU
- Australia
- Prior art keywords
- cancerous
- cell treatment
- substituted nucleoside
- nucleoside derivatives
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97583092A | 1992-11-13 | 1992-11-13 | |
US975830 | 1992-11-13 | ||
US151142 | 1993-11-12 | ||
PCT/US1993/010898 WO1994011003A1 (en) | 1992-11-13 | 1993-11-12 | Cancerous b cell treatment using substituted nucleoside derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5845594A true AU5845594A (en) | 1994-06-08 |
Family
ID=25523453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU58455/94A Abandoned AU5845594A (en) | 1992-11-13 | 1993-11-12 | Cancerous b cell treatment using substituted nucleoside derivatives |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5845594A (en) |
WO (1) | WO1994011003A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576239B1 (en) | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
JP2001501600A (en) * | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | Tumor homing molecules, conjugates derived therefrom, and methods of using the same |
US7544767B2 (en) | 2002-04-05 | 2009-06-09 | Burnham Institute For Medical Research | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
CR20200649A (en) | 2018-05-25 | 2021-05-11 | Primmune Therapeutics Inc | Tlr7 agonists |
IL293293A (en) | 2019-11-26 | 2022-07-01 | Primmune Therapeutics Inc | Tlr7 agonists |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4643992A (en) * | 1982-11-09 | 1987-02-17 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4539205A (en) * | 1982-11-09 | 1985-09-03 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4948730A (en) * | 1982-11-09 | 1990-08-14 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
ATE57187T1 (en) * | 1983-03-30 | 1990-10-15 | Lilly Industries Ltd | VINCALEUKOBLASTIN DERIVATIVES. |
US4746651A (en) * | 1983-11-01 | 1988-05-24 | Scripps Clinic And Research Foundation | Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives |
US4724213A (en) * | 1985-05-24 | 1988-02-09 | Northwestern University | Murine hybridoma Lym-1 and diagnostic antibody produced thereby |
US4801688A (en) * | 1986-05-27 | 1989-01-31 | Eli Lilly And Company | Hydrazone immunoglobulin conjugates |
US4814438A (en) * | 1986-12-24 | 1989-03-21 | Eli Lilly And Company | Immunoglobulin conjugates of 2',2'-difluronucleosides |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
-
1993
- 1993-11-12 AU AU58455/94A patent/AU5845594A/en not_active Abandoned
- 1993-11-12 WO PCT/US1993/010898 patent/WO1994011003A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1994011003A1 (en) | 1994-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3978689A (en) | Nucleoside derivatives | |
AU2883989A (en) | Avermectin derivatives | |
AU2867189A (en) | Dideoxydidehydrocarbocyclic nucleosides | |
AU1444488A (en) | Therapeutic nucleosides | |
AU3388893A (en) | Pyrimidine derivatives | |
AU8038491A (en) | Purine derivatives | |
AU1480497A (en) | Cancer treatment | |
AU617210B2 (en) | Therapeutic nucleosides | |
AU3526989A (en) | 2-amino-pyrimidine derivatives | |
AU5737494A (en) | Human thrombospondin-4 | |
AU5340594A (en) | Skin treatment | |
AU5845594A (en) | Cancerous b cell treatment using substituted nucleoside derivatives | |
AU3170293A (en) | Therapeutic nucleosides | |
AU1318588A (en) | Therapeutic nucleosides | |
AU4508493A (en) | Therapeutic nucleosides | |
AU3607189A (en) | Pyrimidine derivatives | |
AU3719489A (en) | Purine derivatives | |
AU3434489A (en) | Skin treatment formulations | |
AU4334297A (en) | Antiviral treatment | |
AU2200092A (en) | Therapeutic nucleosides | |
AU7112891A (en) | Therapeutic nucleosides | |
AU5165993A (en) | Pp14-based therapy | |
AU2641192A (en) | Therapeutic nucleosides | |
AU632369C (en) | Therapeutic nucleosides | |
AU632369B2 (en) | Therapeutic nucleosides |